Emergent BioSolutions Notified by HHS That Its Proposal to Provide 25 Million Doses of Its Recombinant Anthrax Vaccine Is Technically Acceptable and Within the Competitive Range
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Department of Health and Human Services (HHS) has informed the company that its proposal to provide a recombinant protective antigen...
Emergent BioSolutions Receives $24 Million Development Contract from the Department of Health and Human Services to Fund Continued Development of Anthrax Monoclonal Antibody
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has received a contract from the Department of Health and Human Services (HHS) for over $24.3 million to fund the further development of...
Emergent BioSolutions Reports Financial Results for Second Quarter 2008
In Q2 2008 revenue over Q2 2007 -- Recent acquisitions expand anthrax franchise -- Financial outlook for 2008 is reaffirmed. ROCKVILLE, Md., Aug 07, 2008 (BUSINESS WIRE) -- Emergent BioSolutions Inc....
Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and Human Services (HHS) for...
Statement by Emergent BioSolutions in Response to Attempt by Protein Sciences Corporation to Terminate Asset Purchase Transaction
Emergent BioSolutions Inc. (NYSE:EBS) issued the following statement in response to the announcement by Protein Sciences Corporation (PSC) that PSC is attempting to terminate its asset purchase...
Emergent BioSolutions to Release Second Quarter 2008 Financial Results and Conduct a Conference Call on August 7, 2008
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will report financial results for the second quarter of 2008 on Thursday, August 7, 2008, before market open. Company management will...
Emergent BioSolutions Awarded Two Grants from NIAID to Support Development of the Company’s Recombinant Botulinum Vaccine (rBOT) and Next Generation Anthrax Vaccine (NGAV) Candidates
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has secured two grants totaling over $4.5 million from The National Institute of Allergy and Infectious Diseases (NIAID) to fund the...
Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced Tuberculosis Vaccine with Funding from Wellcome Trust and Aeras Global TB Vaccine Foundation
Wellcome Trust and Aeras Global TB Vaccine Foundation have agreed to provide GBP 8 million in funding for Phase IIb clinical trial that is expected to commence in 2009. The vaccine candidate, MVA85A,...
Emergent BioSolutions Initiates Lawsuit Against Protein Sciences and Its Senior Management Regarding Delayed Asset Acquisition
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has initiated a lawsuit against Protein Sciences Corporation (PSC) and its senior management in connection with a pending acquisition of...
Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced today that dosing of patients has begun in a U.S. Phase II clinical trial of the company's single-dose oral typhoid vaccine candidate. This randomized,...
Emergent BioSolutions and the European Corporate Security Association (ECSA) Sponsor a Conference on Bioterrorism
June 5, 2008--Emergent BioSolutions Inc. (NYSE:EBS) co-sponsored the European Corporate Security Association (ECSA) Conference on Bioterrorism. Today's conference brought together security officials...
Emergent BioSolutions to Webcast Presentation at the Jefferies and Company 2nd Annual Healthcare Conference on June 25, 2008
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Jefferies and Company 2nd Annual Healthcare Conference scheduled for Wednesday June...